Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

Kennedy’s commitment to walk away from the potential windfall is a major reversal for the nominee, who in his ethics plan ...

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...

If confirmed as health secretary, Robert F. Kennedy Jr. would oversee the Food and Drug Administration and other agencies ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Senators had objected to the financial conflict posed by Robert F. Kennedy Jr.’s decision to retain a financial stake in ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Yahoo Finance senior health reporter Anjalee Khemlani explains the process and the range of other drugs on this new list from pharmaceutical giants Pfizer (PFE), AstraZeneca (AZN), Merck (MRK ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...